Fatores de risco e mortalidade de infecções da corrente sanguínea por Klebsiella pneumoniae and Escherichia coli produtores de beta-lactamase de espectro estendido by Superti, Silvana Vargas et al.
Rev. Inst. Med. trop. S. Paulo
51(4):211-216, July-August, 2009
doi: 10.1590/S0036-46652009000400006
(1) Laboratory of Microbiology, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil.
(2) Dept. Internal Medicine, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil.
(3) Infectious Diseases Service, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Correspondence to: Silvana Vargas Superti. Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Laboratório de Microbiologia, Av. Ipiranga 6690, 90610-000 Porto 
Alegre, RS, Brasil. Tel./Fax: +55.51.3320-3145. E-mail: silvanas@ufcspa.edu.br 
RISK FACTORS FOR AND MORTALITY OF EXTENDED-SPECTRUM-b-LACTAMASE-PRODUCING 
Klebsiella pneumoniae AND Escherichia coli NOSOCOMIAL BLOODSTREAM INFECTIONS
 
Silvana Vargas SUPERTI(1), Gustavo AUGUSTI(2) & Alexandre Prehn ZAVASCKI(3)
SUMMARY
A case-control study, involving patients with positive blood cultures for Klebsiella pneumoniae (KP) or Escherichia coli (EC) 
EC and controls with positive blood cultures for non-ESBL-KP or EC, was performed to assess risk factors for extended-spectrum-b-
lactamase (ESBL) production from nosocomial bloodstream infections (BSIs). Mortality among patients with BSIs was also assessed. 
The study included 145 patients (81, 59.5% with K. pneumoniae and 64, 44.1% with E. coli BSI); 51 (35.2%) isolates were ESBL 
producers and 94 (64.8%) nonproducers. Forty-five (55.6%) K. pneumoniae isolates were ESBL producers, while only six (9.4%) E. 
coli isolates produced the enzyme. Multivariate analysis showed that recent exposure to piperacillin-tazobactam (adjusted Odds Ratio 
[aOR] 6.2; 95%CI 1.1-34.7) was a risk factor for ESBL BSI. K. pneumoniae was significantly more likely to be an ESBL-producing 
isolate than E. coli (aOR 6.7; 95%CI 2.3-20.2). No cephalosporin class was independently associated with ESBLs BSI; however, in a 
secondary model considering all oxymino-cephalosporins as a single variable, a significant association was demonstrated (aOR 3.7; 
95%CI 1.3-10.8). Overall 60-day mortality was significantly higher among ESBL-producing organisms. The finding that piperacillin-
tazobactam use is a risk factor for ESBL-production in KP or EC BSIs requires attention, since this drug can be recommended to limit 
the use of third-generation cephalosporins.
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INTRODUCTION
Klebsiella pneumoniae and Escherichia coli are leading causes of 
nosocomial infections, notably pneumonia and urinary tract infection, 
and common bloodstream infections (BSIs)1. Extended-spectrum-ß-
lactamases (ESBLs) have emerged worldwide as a major determinant 
of antimicrobial penicillin, cephalosporin and aztreonam resistance 
among these Gram-negative bacteria19. As occurs in many Brazilian 
hospitals7,14,16, ESBL-producing organisms are endemic and highly 
prevalent in our institution.
Some investigations have shown that ESBL production adversely 
affects important clinical outcomes of patients with Enterobacteriaceae 
BSI, including mortality22. The identification of exposures associated with 
infection by resistant pathogens has been attempted in order to potentially 
correct modifiable variables and to improve knowledge regarding both 
the epidemiology and pathogenesis of resistant organisms26. Additionally, 
the identification of risk factors may help clinicians in their choices of 
empirical antibiotic therapy for individual patients, potentially resulting 
in better outcomes for patients with such infections.
Although risk factors for ESBL have been frequently explored in 
the literature, fewer studies have focused on the identification of risk 
factors for ESBL in patients with BSIs4,6,10,11,13,15,17,20-24. However, these 
studies usually consider antibiotic exposure as a single variable and/or 
have not performed multivariate analysis. Thus, very few studies have 
appropriately investigated the association of each antibiotic class or 
specific antibiotic with ESBL production by bloodstream K. pneumoniae 
and E. coli isolates6,15,21,24. The aim of this study was to assess risk factors 
for ESBL producing K. pneumoniae (ESBL-KP) and E. coli (ESBL-EC) 
nosocomial BSI, with particular focus on the role of distinct antibiotic 
classes. A secondary goal was to compare the mortality of patients with 
ESBL producing organisms BSI with those with non-ESLB pathogens.
MATERIAL AND METHODS
A case-control study was performed in a 600-bed tertiary-care 
teaching hospital in Porto Alegre, Southern Brazil. The Laboratory of 
Microbiology database was used to search for cases. Those involving 
positive blood cultures for K. pneumoniae and E. coli, from June 2004 
to March 2006, were eligible for the study. Patients were excluded when 
they were less than or equal to 18 years-old and when blood culture was 
collected less than 48 hours after hospital admission, unless the patient 
had been hospitalized within the previous 60 days. Data were collected 
SUPERTI, S.V.; AUGUSTI, G. & ZAVASCKI, A.P. - Risk factors for and mortality of extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial 
bloodstream infections. Rev. Inst. Med. trop. S. Paulo, 51(4): 211-216, 2009.
212
from medical records and/or hospital computer system databases. The 
primary site of infection was defined according to CDC criteria8. The 
hospital’s Ethics Review Board approved this study. Written informed 
consent was not required because it was a retrospective study.
The isolates were identified by conventional microbiological 
methods and commercial systems, including API20E® (bioMérieux) 
and AutoScan-4® (Dade Behring). Antimicrobial susceptibilities were 
determined by disk diffusion, according to Clinical Laboratory Standards 
Institute (CLSI) recommendations3. All K. pneumoniae and E. coli 
isolates were screened for potential ESBL production using screening 
breakpoints proposed by the CLSI, with ceftazidime, cefotaxime, 
ceftriaxone and aztreonam disks. For phenotypic confirmatory test, 
Mueller-Hinton agar plates (bioMérieux®) with disks containing 30 μg 
of ceftazidime and disks containing 30 μg of cefotaxime (OXOID®), 
with and without 10 μg of clavulanic acid were used and interpreted, as 
recommended by the CLSI3. 
The cases were patients with nosocomial BSI by ESBL-KP or EC and 
controls were patients with BSI by non-ESBL-KP or EC. The variables 
potentially associated with the ESBL infections included: age; sex; 
Charlson comorbidity index score2; Pitt bacteremia score18; iatrogenic 
immunosuppression, such as chemotherapy-induced neutropenia 
(neutrophil count < 1,000 cells/mm3), and/or receipt of corticoid drugs 
or other immunosuppressive agents for less than 14 days; time at risk 
(length of hospital stay before K. pneumoniae or E. coli recovery); 
previous surgical procedure during hospital stay; intensive care unit 
(ICU) admission; mechanical ventilation; primary site of infection; 
presence of other infections; polymicrobial bacteremia; antimicrobial 
exposure (only those used for at least 48 hours during the previous 14 
days were analyzed): b-lactams, including monobactams (aztreonam), 
first-generation cephalosporins (cefadroxil, cephalexin, cefazolin 
and cephalothin), second-generation cephalosporins (cefuroxime 
and cefuroxime axetil), cephamycins (cefoxitin), third-generation 
cephalosporins (ceftriaxone and ceftazidime), fourth-generation 
cephalosporins (cefepime), ureidopenicillins and b-lactamase inhibitor 
(piperacillin-tazobactam), carbapenems (ertapenem, imipenem and 
meropenem), fluoroquinolones (ciprofloxacin and levofloxacin), 
aminoglycosides (gentamicin and amikacin), anaerobicidal agents 
(clindamycin and metronidazole) and glycopeptides (vancomycin); and 
exposure to more than one of the antibiotics studied.
All statistical analyses were performed using SPSS for Windows, 
Version 13.0. Bivariate analysis was performed separately for each of the 
variables. Odds ratios (OR) and 95% confidence intervals (95%CI) were 
calculated for binomial variables. P values were calculated using the Chi 
square or Fisher exact tests for categorical variables and the Student t or 
Wilcoxon rank-sum tests for continuous variables. Variables for which 
the p value was ≤ 0.10 in bivariate analysis were included one by one in 
a logistic regression model according their p value and the magnitude 
of their effect. A p of 0.10 was set as the limit for acceptance or removal 
of the new terms in the model. 
Overall 60-day mortality was assessed and the relative risk (RR) was 
calculated. Survival curves were prepared using Kaplan-Meier estimation 
and compared using the log-rank test. All tests were two-tailed and p ≤ 
0.05 was considered significant. 
RESULTS
A total of 145 patients were included in the study. Eighty-one 
(59.5%) isolates were K. pneumoniae and 64 (44.1%) were E. coli. 
Fifty-one (35.2%) isolates were ESBL producers and 94 (64.8%) were 
nonproducers. The incidence of BSIs due to ESBL-KP or EC and non-
ESBL-KP or EC isolates was not significantly different for any month 
for either hospital throughout the study (p = 0.24). ESBL production 
was significantly more frequent among K. pneumoniae (45, 55.6% of 
the isolates) than E. coli (6, 9.4% of the isolates), p ≤ 0.001. No isolate 
presented resistance to carbapenems. Resistance to any of the drugs 
tested was significant (p < 0.05) and more frequently observed in ESBL 
producer organisms than non-ESBL (data not shown), including second, 
third and fourth-generation cephalosporins, cefoxitin, piperacillin-
tazobactam, aztreonam, ciprofloxacin and amikacin.
The results of bivariate analysis of risk factors for ESBL-KP or 
EC BSI are presented in Table 1. None of the patients were exposed to 
aztreonam or cefoxitin, so these agents are not presented in the analysis. 
The results of the multivariate analysis showed that recent use of 
the combination antibiotic piperacillin-tazobactam (adjusted [a] OR 
6.2; 95%CI 1.1-34.7; p = 0.04) was the most important risk factor for 
ESBL BSI. BSI due to K. pneumoniae, rather than E. coli, was also 
independently associated with ESBL (aOR 6.7; 95%CI 2.3-20.2; p < 
0.001). Pitt bacteremia score remained in the final model, but showed no 
statistical significance (aOR 1.1; 95%CI 1.0-1.3; p = 0.16). Second, third 
or fourth-generation cephalosporins did not present statistical significance 
in the multivariate analysis, so none of these drugs remained in the final 
model. No other variable remained in the final model. 
Considering a potential b error due to low exposure to oxymino-
cephalosporins (i.e. second-, third- and fourth-generation cephalosporins) 
in both cases and controls, a secondary model was performed including 
all these drugs as a single variable, which were included individually 
in the first model. In bivariate analyses, oxymino-cephalosporins 
were significantly associated with ESBL BSI (OR 3.5; 95%CI 1.5-
8.2; p = 0.007). The results of this second multivariate model showed 
that piperacillin-tazobactam (OR 6.7; 95%CI 1.3-35.1; p = 0.03) 
and K. pneumoniae (OR 8.3; 95%CI 2.5-27.5; p < 0.001) remained 
independently associated with ESBL BSI, as determined in the main 
model and that oxymino-cephalosporins (OR 3.7; 95%CI 1.3-10.8; p = 
0.02) were also associated with ESBL BSI. Pitt bacteremia score was 
also maintained in the final model, but with no statistical significance 
(p = 0.12).
Overall 60-day mortality of patients with KP or EC BSI was 37.2% 
(54 of 145 patients) and was significantly higher among patients with 
BSI by ESBL than non-ESBL producers (26 out of 51 [51.0%] versus 
28 out of 94 patients [29.8%], respectively, RR 1.71, 95%CI 1.14-2.58, 
p = 0.019). The mortality rate was 26.0 per 1000 patient-days among 
patients with ESBL BSIs and 16.4 per 1000 patient-days among those 
with non-ESBL BSIs (p = 0.08). However, according to survival curves, 
mortality rates were higher, though not statistically significant (p = 
0.99), among patients with non-ESBL BSIs during the first 14 days 
(41.6 per 1000 patient-days) than among those with ESBL BSIs (22.1 
per 1000 patient-days). These rates were significantly higher among 
ESBL-producing organisms after this period: 22.2 per 1000 patient-days 
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Table 1
 Bivariate analysis of the risk factors for extended-spectrum-b-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli 
nosocomial bloodstream infection





Klebsiella pneumoniae infection 45 (73.8) 36 (38.3) < 0.001
Age, years 61.7 ± 18.1 58.7 ± 17.4 0.34
Sex, male 32 (62.7) 49 (52.1) 0.29
Charlson score, median (25-75% percentile) 3 (2-6) 3 (2-5) 0.72
Pitt bacteremia score, median (25-75% percentile) 2 (0-4) 0 (0-2) 0.04
Iatrogenic immunosuppression 9 (17.6) 24 (25.5) 0.38
Length of hospital stay, days 26 ± 20 16 ± 16 0.002
Intensive Care Unit admission 26 (51.0) 27 (28.7) 0.01
Mechanical ventilation 17 (33.3) 12 (12.8) 0.006
Previous surgery 35 (68.6) 43 (45.8) 0.04
Site of infection
 Lower respiratory tract 14 (27.5) 11 (11.7) 0.03
 Urinary tract 7 (13.7) 26 (27.7) 0.09
 Skin and soft tissue 0 (0) 1 (1.1) 0.65
 Central venous catheter 11 (21.6) 14 (14.9) 0.43
 Intraabdominal 2 (4.0) 8 (8.5) 0.25
 Primary bloodstream 16 (31.4) 32 (34.0) 0.89
 Central Nervous System 0 (0) 2 (2.1) 0.42
 Bone 1 (2.0) 0 (0) 0.35
Other infections 14 (27.5) 14 (14.9) 0.11
Polymicrobial infection 27 (52.9) 90 (95.8) 0.10
Presence of urinary catheter 32 (62.7) 38 (40.4) 0.02
Presence of central venous catheter 32 (62.7) 40 (42.6) 0.03
Antibiotic exposure 
 b-lactams b
 First-generation cephalosporin 1 (2.0) 3 (3.2) 0.41
 Second-generation cephalosporin 3 (5.9) 0 (0) 0.08
 Third-generation cephalosporins 4 (7.8) 2 (2.1) 0.11
 Cefepime 12 (23.5) 9 (9.6) 0.12
 Piperacillin-tazobactam 8 (15.7) 1 (1.1)  0.01
 Carbapenems 4 (7.8) 7 (7.5) 0.58
Fluoroquinolones c 13 (25.5) 20 (21.3) 0.71
Aminoglycosides d 1 (2.0) 2 (2.3) 0.72
Vancomycin 9 (17.6) 8 (8.5) 0.55
Anaerobicidal e 17 (33.3) 12 (12.8) 0.09
Use of more than one of the antibiotics studied f 17 (33.3) 11 (11.7) 0.003
+, producer; -, nonproducer; a All variables are expressed as the mean ± SD or number (%), unless otherwise indicated; b First-generation cephalosporin: all 3 were 
cephalothin; Second-generation cephalosporin: all were 3 cefuroxime; Third-generation cephalosporins: all 6 were ceftriaxone; Carbapenems: 6 were meropenem and 
5 were imipenem; c Nineteen ciprofloxacin and 14 levofloxacin; d Two amikacin and 1 gentamicin; e Twenty clindamycin and 9 metronidazole; f Fifteen (51.8%) double 
exposures were to a second-, third- or cefepime and a anaerobicidal agent; 6 (20.7%) were to ciprofloxacin and anaerobicidal; 3 (10.3%) were to cefepime and van-
comycin; 2 (6.9%) were to a carbapenem and vancomycin; 1 (3.5%) was to piperacillin-tazobactam and ciprofloxacin; 1 (3.5%) was to cephalothin and ciprofloxacin; 
and 1 (3.5%) was to ceftriaxone and ciprofloxacin.
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among patients with ESBL BSIs and 7.1 per 1000 patient-days among 
those with non-ESBL BSIs (p = 0.03).
DISCUSSION
ESBL-producing organisms are a clinical problem worldwide, 
particularly in Latin American countries and especially in Brazil, where 
high endemic rates of ESBL-producing Enterobacteriaceae have been 
determined7,14,16. In our institution, high endemic rates have also been 
observed over the last 10 years. The present study showed that more than 
half (55.6%) of K. pneumoniae BSIs are caused by ESBL producers, a 
fact of grave concern. 
This study showed that use of the combination antibiotic piperacillin-
tazobactam within the previous 14 days was strongly associated with 
ESBL production in BSIs due to KP or EC. Additionally, K. pneumoniae 
BSIs occurred more frequently due to an ESBL-producing organism 
than E. coli BSIs.
Only one prior study has reported that piperacillin-tazobactam may 
be a risk factor for ESBL-KP or EC colonization9. The present work 
demonstrated a strong independent association of this combination of 
drugs with ESBL-KP or EC BSI; however, it should be noted that ESBL 
isolates presented significantly higher rates of piperacillin-tazobactam 
resistance than non-ESBL ones. This indicates that another resistance 
mechanism was probably present among ESBL producers, since ESBL 
is inhibited in vitro by tazobactam19. Thus, piperacillin-tazobactam 
exposure could actually be associated with the selection of isolates 
producing this other resistance mechanism, which was more frequently 
observed in ESBL isolates in the present study. Regardless of the cause 
of this association, this finding has important implications, since some 
antimicrobial drug stewardship policies propose an increase in the use 
of certain antimicrobial drugs, including piperacillin-tazobactam, and a 
reduction in the prescription of third-generation cephalosporins, in an 
effort to control ESBL-producing bacteria9. 
It was not possible to demonstrate an independent association of any 
specific class of cephalosporin with ESBL. However, this may be due to 
a reduced statistical power due to the low exposure rates of each class 
than to the lack of a real association of the variables with the outcome, 
since a significant association was demonstrated when reducing b-error 
by analyzing all oxyimino-cephalosporins together as a single variable. 
Furthermore, cephalosporins, particularly oxyimino-cephalosporins, have 
been shown to be risk factor for ESBL in other studies15,19,21.
No association between fluoroquinolone or aminoglycoside exposure 
and ESBL-KP or EC BSIs was observed, as previously determined19, 
despite the fact that ESBL-producing organisms presented significantly 
more resistance to both classes of drugs than nonproducing isolates. 
Although the low exposure rates might explain the lack of association 
with aminoglycosides, this was not the case of fluoroquinolones. The 
use of more than one antibiotic by the same patient was statistically 
significant in bivariate analysis, but this was not the case in any of the 
regression models. We believed that this occurred because most of the 
double exposures (51.8%) involved an oxyimino-cephalosporin and an 
anaerobicidal agent and another five (17.2%) involved an oxyimino-
cephalosporin or piperacillin-tazobactam and another non-significantly 
associated drug (vancomycin or ciprofloxacin).
In the present study, inclusion of the causative agent of BSI, K. 
pneumoniae or E. coli, in the multivariate model was proposed in order 
to control potential risk factors associated with the bacteria rather than 
with ESBL production. The finding that K. pneumoniae was significantly 
associated with ESBL production merely reflects local and worldwide 
epidemiology, which clearly show that ESBL production has been more 
frequently observed in this bacteria than in E. coli19. 
Overall 60-day mortality was significantly higher in ESBL patients 
than non-ESBL patients (51.0% versus 29.8%, respectively). Although 
not statistically significant, an important trend toward higher mortality 
rates among former patients was demonstrated in this study. Of note, 
mortality rates of patients with both ESLB and non-ESBL organisms 
were significantly higher after the end of the second week of the onset 
of BSI. The cause of this interesting finding was not assessed in this 
work and should be further explored. It should be noted that only crude 
mortality rates are presented, because this was not the main objective of 
the study. No adjustment for any potential confounding variables was 
performed and this should be considered while interpreting the results.
The study has some limitations that should be acknowledged, 
besides those common to all studies with a retrospective design. 
First, we were unable to assess the dose and duration of antimicrobial 
therapy, thus no potential dose-response effect could be determined. 
Additionally, data regarding the molecular epidemiology of ESBL-
KP or EC bloodstream isolates was not presented, neither for the 
characterization of the ESBL type nor for isolate typing. However, 
we believe that this has little or no impact on our main findings, with 
the exception that the role of potential horizontal-transmission could 
not be determined. Finally, although use of the combination antibiotic 
piperacillin-tazobactam was shown to be independently associated 
with ESBL, this finding was based on a relatively small number of 
observations (eight cases and one control); thus caution is required 
when generalizing the results, as well as additional confirmation in 
future studies. 
Fig. 1 - Mortality curves of patients with bloodstream infections due to extended-spectrum 
ß-lactamases (ESBLs) and non-ESBL-producing Klebsiella pneumoniae (KP) or Escherichia 
coli (EC). Curves were prepared using Kaplan-Meier estimation and compared using the 
log-rank test (p = 0.08).
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The issue of control selection in case-control studies that assess risk 
factors for antibiotic-resistant organisms has been matter of debate5,12,25. 
Patients with non-ESBL-KP or EC BSI were chosen, because this design 
is well suited to assess risk factors when trying to determine which 
variables are associated with antibiotic resistance among patients with 
infections by specific organisms5,12.
In conclusion, analysis of the results showed that exposure to 
piperacillin-tazobactam was a risk factor for ESBL production among 
KP or EC isolates causing BSIs. Although ESBL BSI was not associated 
with any specific class of cephalosporin, when considering all oxyimino-
cephalosporins together, an independent association was observed. 
Overall 60-day mortality was significantly higher among ESBL-
producing bacteria, but the specific mediators of this effect and potential 
confounding factors were not investigated. Particular attention must be 
given to the potential risks of exposure to piperacillin-tazobactam, since 
the prescription of this drug has been recommended by some antibiotic 
stewardship programs in order to limit third-generation cephalosporin 
use. Further studies assessing the association of this specific drug with 
ESBL are required. 
RESUMO
Fatores de risco e mortalidade de infecções da corrente sanguínea 
por Klebsiella pneumoniae and Escherichia coli produtores de 
beta-lactamase de espectro estendido
Estudo de caso-controle, onde os casos foram pacientes com 
hemocultura positiva para Klebsiella pneumoniae (KP) ou Escherichia 
coli (EC) produtores de beta lactamase de espectro estendido (ESBL) 
e os controles foram pacientes com hemoculturas positivas para EC 
ou KP não produtores de ESBL foi realizado para avaliar os fatores de 
risco para produção destas enzimas em infecções da corrente sanguínea 
(ICS). Mortalidade dos pacientes com ICS também foi avaliada. Foram 
incluídos 145 pacientes (81, 59,5% tinham Klebsiella pneumoniae e 64, 
44,1% tinham Escherichia coli); 51 (35,2%) isolados eram produtores 
de ESBL e 94 (64,8%) eram não produtores. Quarenta e cinco (55,6%) 
isolados de K. pneumoniae e somente seis (9,4%) isolados de E. coli 
eram produtores de ESBL. Análise multivariada mostrou que exposição 
recente a piperacilina-tazobactam (OR ajustado [aOddsRatio] 6,2; 95% 
Intervalo de Confiança [IC] 1,1-34,7) foi fator de risco para infecção da 
corrente sanguínea por ESBL. Foi significativamente maior a chance 
de K. pneumoniae ser um isolado produtor de ESBL do que E. coli 
o ser (aOR 6,7; 95% CI 2,3-20,2). Nenhuma classe de cefalosporina 
foi independentemente associada com ESBL-ICS. No entanto, em um 
modelo secundário considerando todas as oximino-cefalosporinas como 
variável única, foi demonstrada associação significativa (aOR 3,7; 95% 
IC 1,3-10,8). Mortalidade total em 60 dias foi significativamente maior 
entre isolados produtores de ESBL. O achado de piperacilina-tazobactam 
como fator de risco para produção de ESBL em ICS por KP ou EC requer 
atenção, uma vez que esta droga tem sido eventualmente recomendada 
para poupar o uso de cefalosporinas de terceira geração. 
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